Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03115489|
Recruitment Status : Withdrawn (Low eligibility of patients, no successful recruitment)
First Posted : April 14, 2017
Last Update Posted : May 21, 2021
|Condition or disease||Intervention/treatment||Phase|
|Refractory Epilepsy||Drug: Traditional Treatment (Group T) Drug: Ketamine Infusion (Group K)||Phase 2 Phase 3|
The traditional treatment for refractory status epilepticus includes diazepam, midazolam, valproic acid, thiopental and propofol. These medications fail to control seizure activity in 20-40% of patients. This is attributed to decrease in activity of gamma-aminobutyric acid receptors along with reciprocal up regulation of N-Methyl-D-aspartate receptors. Glutamate activation of N-methyl-D-aspartate receptors promotes calcium influx and excitotoxicity. Ketamine, an intravenous anesthetic agent which is a non-competitive antagonist of N-methyl-D-aspartate receptors can block the flow of Ca and Na and by combining with phencyclidine binding sites inside the ion channel of N-methyl-D-aspartate receptors, reduce the epileptiform burst discharges and after potential. Therefore, targeting the N-methyl-D-aspartate receptors with ketamine may provide a novel approach to control refractory seizures. Moreover, by blocking glutamate mediated N-methyl-D-aspartate receptor induced neurotoxicity, ketamine may render neuroprotection. Ketamine also provides additional advantage of hemodynamic stability. Currently, ketamine is used as a last resort drug in the treatment of refractory status epilepticus.
The specific aim is to determine whether continuous infusion of ketamine as a first line agent for refractory status epilepticus is effective in controlling seizures.
The central hypothesis of our proposal is that early treatment with ketamine will be much more efficacious in controlling refractory status compared to the traditional treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus- a Pilot Study|
|Actual Study Start Date :||May 4, 2017|
|Actual Primary Completion Date :||December 31, 2019|
|Actual Study Completion Date :||May 18, 2021|
Placebo Comparator: Traditional Treatment (Group T)
Group T patients will be placed into burst suppression with the traditional drug infusions which include any single or combination of drugs; usually benzodiazepines, barbiturates and or propofol.
Drug: Traditional Treatment (Group T)
Patients will receive traditional drug infusions
Other Name: benzodiazepines, barbiturates, propofol
Active Comparator: Ketamine Infusion (Group K)
Patients in the group K arm will receive a loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached. After 48 hours of burst suppression the ketamine dosage will be reduced by 2mg/kg/hr in a stepwise fashion to evaluated for EEG or clinical evidence of seizure recurrence.
Drug: Ketamine Infusion (Group K)
Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
Other Name: Ketalar
- Time taken for burst suppression [ Time Frame: Baseline to 1 hr ]Average time for burst suppression
- Time taken for termination of seizures [ Time Frame: Baseline to 24 hrs ]Average time for seizures to terminate
- Use of vasopressors [ Time Frame: baseline to 72 hrs ]The need of vasopressors
- Number of days on ventilator [ Time Frame: Baseline to 72 hrs ]Total number of days patient is on the ventilator
- Length of stay in ICU [ Time Frame: Baseline to 72 hrs postoperatively ]Total number of days in the ICU
- Use of parenteral or enteral nutrition [ Time Frame: Baseline to 72 hrs postoperatively ]Nutrition provided through a feeding tube or catheter
- Medical imaging results [ Time Frame: Post-op Day 2 to Post-op day 10 ]MRI scans 7 to 10 days after burst suppression
- Mortality [ Time Frame: baseline to post-op day 10 ]death
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03115489
|United States, Alabama|
|UAB Department of Anesthesiology and Perioperative Medicine|
|Birmingham, Alabama, United States, 35249|
|Principal Investigator:||Vinodkumar Singh, MD||University of Alabama at Birmingham|